Market revenue in 2023 | USD 37.4 million |
Market revenue in 2030 | USD 54.9 million |
Growth rate | 5.7% (CAGR from 2023 to 2030) |
Largest segment | Crohn's disease |
Fastest growing segment | Ulcerative Colitis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Crohn's Disease, Ulcerative Colitis |
Key market players worldwide | AbbVie Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Biogen Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Merck & Co Inc, Johnson & Johnson, Celltrion Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inflammatory bowel disease treatment market will help companies and investors design strategic landscapes.
Crohn's disease was the largest segment with a revenue share of 60.16% in 2023. Horizon Databook has segmented the Norway inflammatory bowel disease treatment market based on crohn's disease, ulcerative colitis covering the revenue growth of each sub-segment from 2018 to 2030.
Moreover, presence of nonprofit organizations that provide information & train healthcare professionals and support patients affected with ulcerative colitis & Crohn’s disease is anticipated to fuel inflammatory bowel disease treatment market growth.
In addition, the presence of leading market players such as Takeda Pharmaceutical Company Limited, Biogen, Gilead, & Amgen and various strategic initiatives undertaken by them are also major factors impelling market growth.
For instance, in May 2020, Takeda Pharmaceutical Company Limited announced that the European Commission granted marketing authorization to its Entyvio subcutaneous formulation as a maintenance therapy in adults with moderate-to-severe Crohn’s disease & ulcerative colitis.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway inflammatory bowel disease treatment market , including forecasts for subscribers. This country databook contains high-level insights into Norway inflammatory bowel disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account